# A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

> **NCT03970616** · PHASE1,PHASE2 · TERMINATED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tivozanib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03970616
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-30
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-04-04
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.
- **Last updated:** 2023-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03970616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03970616, "A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03970616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*